2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Nivolumab

Nivolumab  (Synonyms: BMS-936558; ONO-4538; MDX-1106)

Cat. No.: HY-P9903 Purity: 99.63%
COA
SDS
Technical Support

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

For research use only. We do not sell to patients.

CAS No. : 946414-94-4

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

Nivolumab Featured Recommendations:

Nivolumab Related Antibodies

Top Publications Citing Use of Products

    Nivolumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2025 May 22;13(5):e011080.  [Abstract]

    Nivolumab (25 µg/mL). FCM analysis of effector cytokine expression, including IFN-γ, in CD8+T cells across different treatment groups. Histogram overlays depict cytokine expression levels, while bar graphs quantify the percentage of GZMB+, IFN-γ+, and perforin+CD8+ T cells.

    Nivolumab purchased from MedChemExpress. Usage Cited in: Adv Healthc Mater. 2025 Nov 28.

    Activated Jurkat cells were treated for 2 h with anti PD-1 monoclonal antibody (Nivolumab, 10 µg/mL) and then co-cultured with cancer-on-a-bead model for an additional 24 h in the continued presence of the antibody. T cells apoptosis/necrosis was analyzed with Annexin/PI staining by flow cytometry. The displayed dot plot represents one experiment, typical of three independent experiments conducted.

    Nivolumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 22;15(1):2567.  [Abstract]

    Representative proliferation assay of co-cultures using patient-derived intratumor NKs and NCI-H23 cells. NK anti-tumor activity was assessed in the presence of BETi (1 µM OTX015) and/or the anti-PD-1 inhibitor Nivolumab (15 µg/mL; 24-72 h) (n = 3 co-cultures from a single patient).

    Nivolumab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Aug 13:e177413.  [Abstract]

    Survival of low-grade glioma GEMM mice using Kaplan-Meier analysis. IgG: n = 20 mice (median survival [MS]: 110.5 days), anti–PD-1 (Nivolumab, 200 μg/mouse; i.p.; three times per week for 3 weeks): n = 20 mice (MS: 134.5 days), anti-TIM3: n = 21 mice (MS: 253 days). Statistics (log-rank test): control versus anti–PD-1 (Nivolumab), P = 0.64; control versus anti-TIM3, P < 0.01; anti-TIM3 versus anti–PD-1 (Nivolumab), P = 0.02.

    Nivolumab purchased from MedChemExpress. Usage Cited in: Mol Ther. 2022 Feb 2;30(2):621-631.  [Abstract]

    IFN-γ does not increase in the context of PD-L1−/P146R relative to PD-L1−/WT. Co-cultures of T cells and the GC cells with or without Nivolumab (1 ng/μL; 4 days). IFN-γ concentration was measured in the supernatant. The results showed that Nivolumab significantly enhanced IFN-γ secretion from T cells.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

    Isotype

    Human IgG4 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    PDCD1/PD-1/CD279
    In Vitro

    Nivolumab binds to CHO cells expressing PD-1 with an EC50 of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC50 of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Nivolumab Related Antibodies
    In Vivo

    Nivolumab (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Gene ID

    5133  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    143.62 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Nivolumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG4 kappa
    Biological Activity
    • Immobilized hu-PD-1-His can bind Nivolumab. The EC 50 for this effect is 6.195 ng/mL.
    • Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Nivolumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells.
    Purity & Documentation

    Purity: 99.63%

    SDS (251 KB)

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Nivolumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Nivolumab946414-94-4BMS-936558 ONO-4538 MDX-1106BMS936558BMS 936558ONO4538ONO 4538ONO-4538MDX1106MDX 1106MDX-1106PD-1/PD-L1PD-1/Programmed death-ligand 1anti-PD-1anti-hPD-1Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Nivolumab
    Cat. No.:
    HY-P9903
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.